Immune response to seasonal influenza vaccine in patients with relapsing- remitting multiple sclerosis receiving long-term daclizumab beta: A prospective, open-label, single-arm study

International Journal of MS Care

Volumn 19, Issue 3, 2017, Pages 141-147

  Mehta, Lahar ^a,c   Umans, Kimberly ^a,d   Ozen, Gulden ^a,e   Robinson, Randy R ^b   Elkins, Jacob ^a  

^a BIOGEN   (United States)

^b ABBVIE INC   (United States)

^c AMGEN INC   (United States)

^d Bioverativ   (United States)

^e Sage Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014925980     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2016-026     Document Type: Article

References (19)

1. Giovannoni G, Gold R, Selmaj K, et al.; SELECTION Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472-481
2. Gold R, Giovannoni G, Selmaj K, et al.; SELECT Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167-2175
3. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418-1428
4. Wiendl H, Gross CC. Modulation of IL-2Ra with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394-404
5. Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2011;8:143-151
6. Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84:872-879
7. Pellegrino P, Carnovale C, Perrone V, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine. 2014;32:4730-4735
8. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. 2014;20:1074-1080
9. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology. 2006;26:102-107
10. Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology. 2014;83:929-937
11. Gold R, Radue EW, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016;16:117
12. The European Agency for the Evaluation of Medical Products, Human Medicines Evaluation Unit. Note for guidance on harmonisation of requirement for influenza vaccines. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf. Published March 12, 1997. Accessed December 1, 2015
13. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. http://www.fda.gov/cber/gdlns/trifluvac. htm. Published May 2007. Accessed December 1, 2015
14. Seidman JC, Richard SA, Viboud C, Miller MA. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses. 2012;6:52-62
15. Lin YC, Winokur P, Blake A, et al. Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm. 2016;3:e196
16. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81:552-558
17. Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34:730-733
18. Schwid SR, Decker MD, Lopez-Bresnahan M; Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65:1964-1966
19. Mehling M, Fritz S, Hafner P, et al. Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy. PLoS One. 2013;8:e78532